A new JAMA Psychiatry randomized trial ↗ reports that semaglutide ↗, the GLP-1 receptor agonist sold as Ozempic ↗ and Wegovy ↗, significantly improved measures of motivation in patients with major depressive disorder. The result is a primary signal on what depression researchers call effort-based decision-making, and it is the first randomized controlled evidence that GLP-1 drugs touch the reward circuitry in clinical depression rather than only adjacent metabolic dysfunction.
The trial. Seventy-two participants with MDD and a body mass index of 25 or higher were randomized 1:1 to oral semaglutide (n=35) at 14 mg, titrated up over four weeks, or placebo (n=37), each adjunctive to ongoing treatment as usual. Sixteen weeks, double-blind. Recruited from the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto. Trial registration: NCT04466345. The preregistered outcome of this secondary analysis was performance on the Effort-Expenditure for Rewards Task, a behavioral test where participants choose between a low-effort low-reward option and a high-effort high-reward option across many trials, with the probability of receiving the reward varied between conditions.
The result. Semaglutide-treated participants showed increased willingness to exert physical effort for higher expected reward (treatment by visit by expected value interaction χ² = 12.024, P = 0.02). Computational modeling indicated the effect was driven by reduced effort discounting, the cognitive process where the brain weights future reward against the perceived cost of action. Sensitivity to effort was significantly reduced by semaglutide (β = -1.737, P = 0.03). Sensitivity to reward probability was unchanged. Translated: depressed patients on semaglutide were more willing to do the work for the larger reward, even though their estimation of how likely the reward was had not changed.
Why this matters. Anhedonia, the inability to experience normal pleasure or motivation, is one of the two cardinal symptoms of major depression and one of the hardest to treat. Most antidepressants targeting serotonin and norepinephrine improve mood but leave motivational deficits and effort tolerance unchanged. SSRIs in particular are notoriously weak on this dimension, which is why patients describe their depression "lifting" without the energy to do the things that lifting is supposed to enable. Effort-based decision-making is the lab-based proxy for that gap. A drug class that consistently moves it would be operationally different from anything currently approved.
The mechanism context. GLP-1 receptors are densely expressed in mesolimbic reward circuitry, including the ventral tegmental area, the nucleus accumbens, and pathways feeding into them. The peptidemodel news section recently covered a separate paper showing GLP-1 receptors are also distributed across the cerebellar cortex, where they contribute to appetitive behaviors through projections back into mesolimbic regions. The cumulative picture from the past year of GLP-1 secondary-effects literature is that the receptor's distribution is wider than appetite biology assumed, and the behavioral effects of agonism extend further into reward, motivation, and addiction-adjacent domains than the obesity story predicted.
Caveats. The study is small (n=72) and the primary published analysis is a secondary endpoint of a trial designed for other endpoints. The cohort is BMI ≥25, which means the population overlaps the existing FDA indication for semaglutide; the result does not yet say whether normal-weight depressed patients would benefit. Effort-based decision-making is one slice of motivational behavior, not depression itself, and the abstract release does not include change-from-baseline depression severity scores. Replication in a larger MDD-specific trial is the next step.
What is durable about the result is that it is positive and that it is from a registered RCT rather than an observational cohort. The GLP-1 secondary-effects literature has been heavily observational, with kidney, retinal, atrial fibrillation, and post-viral signals all coming from claims-database analyses. This is the first signal in psychiatric symptoms from a controlled experimental design. If it survives replication, the GLP-1 class becomes the first new depression-adjacent mechanism on the table since ketamine and esketamine, and the case for testing it in primary depression separate from obesity comorbidity becomes harder to argue against.